-70.8%
QXO vs MRNA
-67.9%
-2.9%
-95.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | +5.4% | -5.2% | -0.3% |
| 7D | -7.8% | -1.1% | -6.7% | -7.7% |
| 30D | -18.1% | +126.1% | -144.2% | -29.0% |
| 3M | -25.8% | +190.0% | -215.8% | -39.0% |
| 6M | -41.7% | +157.2% | -198.9% | -51.2% |
| YTD | -36.2% | +388.2% | -424.4% | -52.4% |
| 1Y | -42.1% | +467.0% | -509.1% | -58.1% |
| 3Y | -46.2% | +36.1% | -82.2% | -53.9% |
| All | -70.8% | -67.9% | -2.9% | -73.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling